Jun 26, 2025 Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement Learn More
Jun 24, 2025 Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) Learn More
Jun 11, 2025 Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma Learn More